De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Shree Ram Proteins Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Shree Ram Proteins heeft een totaal eigen vermogen van ₹464.9M en een totale schuld van ₹369.4M, wat de schuld-eigenvermogensverhouding op 79.5% brengt. De totale activa en totale passiva bedragen respectievelijk ₹982.6M en ₹517.7M.

Belangrijke informatie

79.5%

Verhouding schuld/eigen vermogen

₹369.40m

Schuld

Rente dekkingsratio	n/a
Contant	₹970.00k
Aandelen	₹464.91m
Totaal verplichtingen	₹517.65m
Totaal activa	₹982.56m

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Recent updates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Aug 02

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Feb 22

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Nov 23

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Jul 14

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Dec 11

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Nov 06

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Jun 19

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Feb 24

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹920.1M ) SRPL } overtreffen de korte termijn passiva ( ₹413.8M ).

Langlopende schulden: De kortetermijnactiva SRPL ( ₹920.1M ) overtreffen de langetermijnschulden ( ₹103.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 79.2% ) SRPL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van SRPL is de afgelopen 5 jaar gedaald van 97.9% naar 79.5%.

Schuldendekking: De schuld van SRPL wordt niet goed gedekt door de operationele kasstroom ( 1.6% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van SRPL op haar schulden goed worden gedekt door EBIT.

Shree Ram Proteins Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Recent updates

First quarter 2025 earnings released: ₹0.02 loss per share (vs ₹0.01 profit in 1Q 2024)

Full year 2024 earnings released: ₹0.45 loss per share (vs ₹0.18 profit in FY 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Now 22% overvalued after recent price rise

Now 24% overvalued after recent price rise

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.048 profit in 2Q 2023)

Shree Ram Proteins Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Less than half of directors are independent

Full year 2023 earnings released: EPS: ₹0.18 (vs ₹0.29 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: ₹1.79 (vs ₹2.87 in FY 2022)

Investor sentiment improves as stock rises 16%

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorates as stock falls 17%

Chairman & MD recently sold ₹4.9m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.25 (vs ₹0.56 in 3Q 2022)

Chairman & MD recently sold ₹2.0m worth of stock

Investor sentiment deteriorated over the past week

Non Executive Director recently sold ₹7.3m worth of stock

Non Executive Director recently bought ₹40m worth of stock

Insider recently sold ₹2.4m worth of stock

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹1.7m worth of stock

Chairman & MD recently bought ₹2.4m worth of stock

Second quarter 2023 earnings released: EPS: ₹0.48 (vs ₹0.77 in 2Q 2022)

Less than half of directors are independent

Chairman & MD recently bought ₹1.6m worth of stock

Investor sentiment deteriorated over the past week

Promoter & Whole-Time Director recently sold ₹10m worth of stock

Promoter & Whole-Time Director recently sold ₹3.2m worth of stock

Promoter & Whole-Time Director recently sold ₹2.8m worth of stock

Investor sentiment deteriorated over the past week

Shree Ram Proteins Limited, Annual General Meeting, Jul 18, 2022

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Promoter & Whole-Time Director recently sold ₹11m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Chairman & MD recently sold ₹4.5m worth of stock

Investor sentiment deteriorated over the past week

Chairman & MD recently sold ₹2.8m worth of stock

Full year 2022 earnings released: EPS: ₹2.87 (vs ₹0.39 in FY 2021)

Chairman & MD recently sold ₹3.7m worth of stock

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Investor sentiment improved over the past week

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS ₹0.77 (vs ₹1.27 loss in 2Q 2021)

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Full year 2021 earnings released: EPS ₹0.39 (vs ₹1.22 in FY 2020)

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: ₹0.16 loss per share (vs ₹0.22 loss in 3Q 2020)

New 90-day high: ₹37.35

Shree Ram Proteins Limited Announces Board Changes